UroGen Pharma Ltd. — Director's Dealing 2019

Mar 22, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2019-02-06

Reporting Person: Cohen Fred E (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-02-06	Ordinary Shares	M	15000	$16.99	Acquired	15000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-02-06	Stock Option (Right to Buy)	$16.99	M	15000	Disposed	2027-05-15	Ordinary Shares (15000)	Direct

Footnotes

F1: 6.25% of the ordinary shares underlying the stock option vested on each of August 15, 2017, November 15, 2017 and February 15, 2018; 31.25% of the shares vested on May 15, 2018, and the remaining shares vest in 8 equal quarterly installments thereafter.